|Assessment Status||Rapid Review complete|
|Indication||Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy|
|Rapid review commissioned||06/07/2023|
|Rapid review completed||03/08/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that vutrisiran not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.